| Oct 29 |
Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now
|
| Oct 16 |
Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference
|
| Oct 15 |
Immuron Travelan® continued strong sales growth
|
| Oct 4 |
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study
|
| Oct 3 |
Immuron Full Year 2024 Earnings: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)
|
| Sep 24 |
Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now
|
| Sep 5 |
Immuron Plans Phase 2 Trial for IMM-529 following FDA review
|
| Aug 21 |
Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now
|
| Aug 19 |
US DoD grants $2.3m to Immuron for military version of anti-diarrhoeal Travelan
|
| Aug 16 |
Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®
|
